The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis

被引:71
作者
Alava, Monica Hernandez [1 ]
Wailoo, Allan [1 ]
Wolfe, Fred [2 ]
Michaud, Kaleb [2 ,3 ]
机构
[1] Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England
[2] Natl Data Bank Rheumat Dis, Wichita, KS USA
[3] Univ Nebraska, Med Ctr, Dept Med, Omaha, NE 68105 USA
关键词
rheumatoid arthritis; HAQ; pain; EQ-5D; health outcomes; quality of life; economic evaluation; mapping; HEALTH-ASSESSMENT QUESTIONNAIRE; ADJUSTED LIFE YEARS; VALIDITY; EUROQOL; SF-6D;
D O I
10.1093/rheumatology/kes400
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective. This study aims to provide robust estimates of EQ-5D as a function of the HAQ and pain in patients with RA. Method. Repeated observations were made of patients diagnosed with RA in a US observational cohort (n = 100 398 observations) who provided data on HAQ, pain on a visual analogue scale and the EQ-5D questionnaire. We used a bespoke statistical method based on mixture modelling to appropriately reflect the characteristics of the EQ-5D instrument and to compare this with results from standard multiple regression. Results. EQ-5D can be predicted from summary HAQ and pain scores. We identify four different classes of respondents who differ in terms of disease severity. Unlike the multiple regression, the mixture model exhibits very good fit to the data and does not suffer from problems of bias or predict values outside the feasible range. Conclusion. It is appropriate to model the relationship between HAQ and EQ-5D but only if suitable statistical methods are applied. Linear models underestimate the quality-adjusted life year benefits, and therefore the cost-effectiveness, of therapies. The bespoke mixture model approach outlined here overcomes this problem. The addition of pain as an explanatory variable greatly improves the estimates. Reimbursement agencies rely on these types of analyses when formulating policy on the use of new drug therapies. Clinicians as well as economists should be concerned with these issues.
引用
收藏
页码:944 / 950
页数:7
相关论文
共 17 条
[1]
Tails from the Peak District: Adjusted Limited Dependent Variable Mixture Models of EQ-5D Questionnaire Health State Utility Values [J].
Alava, Monica Hernandez ;
Wailoo, Allan J. ;
Ara, Roberta .
VALUE IN HEALTH, 2012, 15 (03) :550-561
[2]
Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis [J].
Bansback, Nick ;
Marra, Carlo ;
Tsuchiya, Aki ;
Anis, Aslam ;
Guh, Daphne ;
Hammond, Tony ;
Brazier, John .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (06) :963-971
[3]
The estimation of a preference-based measure of health from the SF-36 [J].
Brazier, J ;
Roberts, J ;
Deverill, M .
JOURNAL OF HEALTH ECONOMICS, 2002, 21 (02) :271-292
[4]
A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures [J].
Brazier, John E. ;
Yang, Yaling ;
Tsuchiya, Aki ;
Rowen, Donna Louise .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2010, 11 (02) :215-225
[5]
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness [J].
Chen, Y-F ;
Jobanputra, P. ;
Barton, P. ;
Jowett, S. ;
Bryan, S. ;
Clark, W. ;
Fry-Smith, A. ;
Burls, A. .
HEALTH TECHNOLOGY ASSESSMENT, 2006, 10 (42) :1-+
[6]
Valuing Health for Clinical and Economic Decisions: Directions Relevant for Rheumatologists [J].
Harrison, Mark J. ;
Bansback, Nick J. ;
Marra, Carlo A. ;
Drummond, Michael ;
Tugwell, Peter S. ;
Boonen, Annelies .
JOURNAL OF RHEUMATOLOGY, 2011, 38 (08) :1770-1775
[7]
Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis [J].
Harrison, Mark J. ;
Lunt, Mark ;
Verstappen, Suzanne M. M. ;
Watson, Kath D. ;
Bansback, Nick J. ;
Symmons, Deborah P. M. .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2010, 8
[8]
Hurst NP, 1997, BRIT J RHEUMATOL, V36, P551
[9]
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden [J].
Lindgren, Peter ;
Geborek, Pierre ;
Kobelt, Gisela .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 (02) :181-189
[10]
Not all "quality-adjusted life years" are equal [J].
Marra, C. A. ;
Marion, S. A. ;
Guh, D. P. ;
Najafzadeh, M. ;
Wolfe, F. ;
Esdaile, J. M. ;
Clarke, A. E. ;
Gignac, M. A. ;
Anis, A. H. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2007, 60 (06) :616-624